Arrakis Therapeutics logo

Arrakis Therapeutics

Arrakis is developing RNA-targeted small molecule (rSM) therapies to millions of patients.

4

Funding Rounds

$226.0m

Money raised

Overview

Arrakis is developing RNA-targeted small molecule (rSM) therapies to millions of patients.

Funding

Funding series

Funding Series Analysis

The company Arrakis Therapeutics has raised a total of $113m in funding over 4 rounds.

Key Insights:

  • Arrakis Therapeutics Funding Round 2019: $75m
  • Arrakis Therapeutics Series A round, February 2017: $38m
  • Arrakis Therapeutics funding round, April 2019: $75m
  • Arrakis Therapeutics funding round, February 2017: $38m
Arrakis Therapeutics logo
Arrakis Therapeutics Funding Round 2019 $75m
Arrakis Therapeutics logo
Arrakis Therapeutics Series A round, February 2017 $38m
Arrakis Therapeutics logo
Arrakis Therapeutics funding round, April 2019 $75m
Arrakis Therapeutics logo
Arrakis Therapeutics funding round, February 2017 $38m